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Standfirst 
Immunotherapy and modulation of the tumour microenvironment are potential new therapeutic 
approaches that may impact outcome from metastatic prostate cancer. Patient selection may be key 
to deliver benefit from these agents. Studies reported in 2018 suggest that alterations in the 
mismatch repair system and aberrations in CDK12 may represent possible biomarkers of response to 
immunotherapy.   
 
 
  
  
 
Programmed cell death 1 (PD-1) blocking agents have become crucial components of the treatment 
of deadly diseases such as metastatic lung cancer and melanoma, but have also changed the 
treatment paradigm in urologic malignancies such as renal cell carcinoma and bladder cancer1. 
Immune checkpoint inhibitors (ICIs) such as the anti-PD-1 antibody pembrolizumab have received 
FDA approval for the treatment of patients with advanced microsatellite instability-high (MSI-H) or 
DNA mismatch repair-deficient (dMMR) solid tumours2, but their role in the treatment of prostate 
cancer remains unproven.  Here we discuss 4 studies published over the past year that  have 
provided additional insight into the role of immunotherapy in prostate cancer in attempts to 
elucidate whether ICIs can have a meaningful impact in the treatment of metastatic castration 
resistant prostate cancer (mCRPC). The relevance of ICIs in mCRPC has been controversial since 
the cytotoxic T-lymphocyte antigen 4 (CTL-4) targeting antibody (ipilimumab) did not show a survival 
benefit in a phase III randomized trial in molecularly unselected patients.4    
 
Preliminary results from the KEYNOTE-199 phase II trial evaluating the efficacy of pembrolizumab in 
metastatic castration-resistant prostate cancer (mCRPC) were presented by de Bono et al.4 at the 
2018 American Society of Clinical Oncology (ASCO) Annual Meeting. Within this trial, 258 patients 
with mCRPC were treated with single-agent pembrolizumab at progression on standard treatment 
(including docetaxel). Patients were stratified according to programmed cell death 1 ligand 1 (PD-L1) 
positivity and the presence of measurable or bone-only disease; groups included patients with PD-
L1+ measurable disease (cohort 1, n=131), PD-L1− measurable disease (cohort 2, n=67), and bone-
only disease with any PD-L1 status (cohort 3, n=60). Overall, the results of KEYNOTE-199 indicated 
limited anticancer activity of pembrolizumab in molecularly unselected patients with mCRPC — only 
3.5% had radiological responses among patients with measurable disease (n=198; cohorts 1 and 2)  
with no differences between the PD-L1+ and PD-L1– cohorts (4% versus 3%, respectively), with  11% 
of all patients (n = 258) having a PSA decline of >50% and ~10% of patients still on trial at the time of 
the data cut-off. Interestingly, there was limited evidence that responding patients had tumours 
with DNA damage repair pathway aberrations, 4 suggesting that such defects may  represent 
putative biomarkers of response to pembrolizumab .  
  
The preliminary KEYNOTE-199 data are extremely relevant in view of new immunogenomic  insights 
into dMMR mCRPC tumours reported by Nava Rodrigues and colleagues5. The authors report that up 
to 8% of mCRPCs had some evidence of dMMR (with either loss of MMR proteins (MSH2, MSH6, 
MLH1, PMS2) by immunohistochemistry and/or high MSI by other assays) and that dMMR was 
  
associated with poor OS compared with MMR proficient tumours (3.8 versus 7.0 years from the start 
of luteinizing-hormone-releasing hormone (LHRH) antagonist therapy; P=0.005). MSI by targeted 
panel next-generation sequencing (MSINGS) as well as immunohistochemistry and PCR-based assays 
detected dMMR prostate cancers with increased T-cell infiltration and elevated PD-L1 protein 
expression (FIG. 1). MSINGS of mCRPC biopsy samples from the Stand Up To Cancer/Prostate Cancer 
Foundation (PCF/SU2C) cohort (n=254, with 168 having matching transcriptomes) using whole-
exome sequencing (WES) confirmed a strong correlation between WES–MSINGS and targeted panel 
MSINGS scores (r=0.73, P<0.0001). Four dominant mutation signatures matching previously 
described Catalogue of Somatic Mutations in Cancer (COSMIC) mutational signatures were also 
identified — two dMMR-associated signatures, a homologous recombination deficiency (HRD)-
associated signature, and an aging-associated signature. High MSINGS scores were associated with 
dMMR mutational signatures and MMR gene mutations4. The mutational signatures of dMMR CRPCs 
were characterised by increased immune cell, immune checkpoint, and T-cell-associated transcripts, 
including CD200R1, BTLA, PDL1, PDL2, ADORA2A, PIK3CG, and TIGIT5. Together, these findings 
indicate that patients with dMMR prostate cancer are an important subset that merit further 
evaluation of immunotherapy treatment strategies. 
 
The importance of molecular stratification and predictive biomarkers for response to ICIs was 
further demonstrated by Wu and coworkers6, who reported that dMMR and HRD tumours had a 
markedly higher neoantigen burden than other mCRPC molecular subtypes. However, Wu et al.6 
reported that the mutational burden in HRD tumours is predominantly caused by translocations, 
whereas fusions caused by focal tandem duplications contributed to most of the neoantigen burden 
in mCRPCs with biallelic CDK12 inactivating mutations. Neoantigens have strong binding affinities for 
major histocompatibility complex (MHC) class I molecules and therefore are highly immunogenic. 
Moreover, CDK12 mutant tumours had decreased or low expression of chemokines involved in the 
recruitment of regulatory T cells (Tregs), such as C-C motif chemokine 17 (CCL17), CCL20, and CCL22, 
and increased levels of chemokines that support dendritic cell migration into the tumour 
microenvironment, such as CCL21 and CCL25. Consequently, CDK12-mutant tumours with evidence 
of biallelic CDK12 loss had higher overall T cell infiltration (FIG. 1) and greater numbers of expanded 
T cell clones6 compared to tumours without CDK12 or MMR aberrations. In the study by Wu and 
colleagues6, four patients with mCRPC who had biallelic deleterious aberrations in CDK12 were 
treated with an anti-PD-1 agent; two patients had a marked PSA decline but one patient died owing 
to a possible immune-related adverse event. Overall these data support the use of next-generation 
sequencing (NGS)-based patient selection for immunotherapy trials in mCRPC6. 
  
An alternative approach to increase response rates in immunotherapy trials could be through 
modulation of the immunosuppressive tumour microenvironment. Calcinotto and colleagues7 have 
described how interleukin-23 (IL-23) secreted by polymorphonuclear myeloid-derived suppressor 
cells (PMN-MDSCs) in mCRPC tumours can drive resistance to androgen deprivation therapy (ADT). 
MDSCs are known to suppress antitumour immune responses and promote senescence evasion and 
angiogenesis to support tumorigenesis in prostate cancer 8. Calcinotto et al.7 report that mCRPC 
biopsy specimens have higher MDSC counts (CD11b+CD33+CD15+) than castration-sensitive samples 
from the same patient prior to the emergence of ADT resistance. These data were supported in 
mouse models, in which the number of PMN-MDSCs was found to increase over time with the 
emergence of CRPC, and in cell line experiments, whereby MDSC-derived conditioned medium 
sustained cell survival despite androgen deprivation, suggesting that MDSCs regulate androgen-
deprivation sensitivity in a paracrine manner. IL-23 was identified as the major MDSC-derived factor 
driving CRPC, with the frequency of IL-23-producing tumour-infiltrating PMN-MDSCs increasing at 
the emergence of ADT resistance. Intriguingly, C-X-C motif chemokine 5 (CXCL5), which is 
responsible for MDSC chemotaxis via activation of C-X-C chemokine receptor type 2 (CXCR2), was 
also upregulated in CRPC mouse models. These findings were supported in humans, whereby IL23A 
and IL23R mRNA levels were higher in mCRPC biopsy samples than in hormone-naive samples. 
Interestingly, IL-23 was found to regulate the signal transducer and activator of transcription 3 
(STAT3)–retinoid-related orphan receptor γ (RORγ) pathway, which has been reported to drive AR 
and AR splice variant transcription and androgen receptor (AR)-driven signalling in prostate cell lines 
and tumor 9. Overall, these findings could have a meaningful clinical impact given that anti-IL-23 
antibodies are under clinical investigation (for the treatment of psoriasis) and that the CXCR2 
antagonist AZD5069 is being tested in combination with enzalutamide in patients with mCRPC who 
progressed on abiraterone and/or enzalutamide (NCT03177187). 
 In conclusion, immunotherapies are having a major influence on cancer care for many 
cancers and could represent a ‘real hope’ for the treatment of a subset of mCRPC (but not all) as 
suggested by the publications discussed here. However, optimal biomarkers of response to ICIs need 
still to be prospectively validated in clinical trials for mCRPC. Finally, modulation of the tumour 
microenvironment is a new therapeutic approach that could influence patient outcomes, with 
emerging evidence indicating that chronic inflammation promotes prostate carcinogenesis by 
increasing AR signaling10.  
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Pullquotes  
Patients with dMMR prostate cancer and CDK12 mutations are an important subset tha may benefit 
from immunotherapy. 
 
Key Advances  
1. de Bono et al at ASCO 2018 showed that pembrolizumab might be more effective in DDR 
tumors than in unselected patients.  
2. Nava Rodrigues and colleagues reported that a proportion of mCRPC have mismatch repair 
defects associated with altered immune landscapes potentially actionable in 
immunotherapeutic strategies. 
3. Wu et al showed that CDK12 bi-allelic loss defines a molecular subtype of mCRPC 
characterized by increased gene fusions, neoantigen burden, and T cell infiltration 
representing a putative target of immunotherapies. 
4. Calcinotto and colleagues identified IL-23 produced by myeloid-derived suppressor cells as 
driver of castration resistance in prostate cancer. 
 
 
 
 
Figure 1 | T cell infiltration in mCRPC.  
Multi-spectral, multi-colour immunofluorescence images depicting T cell infiltration in lymph node 
biopsy samples from three patients with metastatic castration-resistance prostate cancer (mCRPC). 
Tumours were DNA mismatch repair-deficient (dMMR), DNA mismatch repair-proficient (pMMR), or 
had biallelic CDK12 mutations . dMMR and CDK12 mutant tumors present a considerable higher T-
cell infiltrate. Image courtesy of M. Crespo, The Institute of Cancer Research, London, UK.    
  
 
